ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial Meeting Abstract
| Authors: | Wagner, A. J.; Ravi, V.; Ganjoo, K. N.; Van Tine, B. A.; Riedel, R. F.; Chugh, R.; Cranmer, L. D.; Gordon, E. M.; Hornick, J. L.; Kwiatkowski, D. J.; Du, H.; Grigorian, B.; Schmid, A. N.; Hou, S.; Harris, K.; Desai, N.; Dickson, M. A. |
| Abstract Title: | ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 563s |
| Language: | English |
| ACCESSION: | WOS:000487345804102 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2019.37.15_suppl.11005 |
| Notes: | Meeting Abstract: 11005 -- Source: Wos |
